| Name | Title | Contact Details |
|---|---|---|
Victoria Roberts |
HR Manager | Profile |
Mold Law Groups litigation platform is a culmination of over 15 years of in-depth research by environmentalists, epidemiologists, toxicologists, medical professionals, Neurotoxicologists, Neuropsychologists, and law firms. Our proven methodology, for the first time, provides litigators the ability to couple the human pathogens in an environment to the direct causation of disease within the human body. The development of this cutting-edge science required an understanding of many different scientific disciplines and medical philosophies to provide a unique and new model for mold litigation. This platform is designed to defend or prosecute property and medical damages caused by mold and microbial exposure. Using precision based DNA-PCR sequencing, bacteria culturing, endotoxin testing, (1—>3)β-D beta glucan and other advanced environmental and medical testing, we leverage cutting edge technology and advanced mold litigation techniques to provide our clients with unparalleled and detailed services found nowhere else in our industry. Mold Law Group offers expert witnesses, consulting services, medical resources, legal resources, and environmental resources. We offer these services nationally and internationally. Mold Law Group is the absolute gold standard when it comes to mold litigation consulting.
At Flow, AI isnt just a feature—its the core of everything we do. We are transforming the wholesale insurance industry by building a futuristic insurance brokerage where AI powers every aspect of the experience. With advanced AI features already live in production and actively used by our brokers, we are pioneering Wholesale 3.0, equipping brokers with cutting-edge tools to provide unparalleled service. We are creating an ecosystem of AI agents designed to streamline processes and enhance decision-making in the insurance landscape. The industry relies heavily on text—emails, files, and documents—making Generative AI a perfect fit for solving its challenges. Flow leverages AI to deliver meaningful insights, deep analysis, and white-glove support for every transaction, no matter the deal size. By combining human expertise with Platformless AI, we are bringing back the art of wholesale insurance while eliminating the need for outdated portals. In the past seven months, weve grown 250% month-over-month(!) and are forecasting even more massive growth. Were a Series A startup with over $20M raised from top investors like Lightspeed, MunichRe Ventures, and industry angels.
IDB Bank is an American multinational private and commercial bank headquartered in New York City. It operates in the United States, Latin America, and Israel, and is chartered by the State of New York. As a member of the Federal Deposit Insurance Corporation (FDIC), IDB Bank provides a range of financial services. The bank offers personal banking services, including checking and savings accounts, credit cards, personal loans, and mortgages. For businesses, it provides commercial loans, lines of credit, cash management services, and business checking accounts. Additionally, IDB Bank offers investment products and wealth management services, catering to both individual and business financial needs. With a history dating back to 1949, IDB Bank has evolved from a representative office to a full-service bank, reflecting its commitment to serving a diverse client base across its operational regions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
McLaren Racing was founded by racing driver Bruce McLaren in 1963. The team entered its first Formula 1 race in 1966. McLaren has since won 21 Formula 1 world championships, 189 Formula 1 Grands Prix, the Indianapolis 500 three times, and the Le Mans 24 Hours at its first attempt. McLaren Racing competes across six racing series. The team competes in the FIA Formula 1 World Championship with McLaren F1 drivers Lando Norris and Oscar Piastri, the NTT INDYCAR SERIES with Arrow McLaren drivers Pato OWard, Alexander Rossi and Nolan Siegel, the ABB FIA Formula E World Championship with NEOM McLaren Formula E Team drivers Sam Bird and Taylor Barnard, the Extreme E Championship with NEOM McLaren Extreme E Team drivers Cristina Gutiérrez and Mattias Ekström, and F1 Academy with ART Grand Prix and Driver Development programme member Bianca Bustamante. The team also competes in the F1 Sim Racing Championship as McLaren Shadow, having won the 2022 Constructors and Drivers Championships. McLaren is a champion for sustainability in the sport and a signatory to the UN Sports for Climate Action Commitment. It is committed to achieving net zero by 2040 and fostering a diverse and inclusive culture in the motorsport industry.